A part of Watch Media

MedWatchSaturday4 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
11/05/2022at 14:17

Lundbeck CEO expects migraine market to grow following Pfizer's billion-dollar acquisition

The USD 11.6bn acquisition bid for migraine firm Biohaven Pharmaceuticals would make Pfizer a direct competitor to Lundbeck. Even so, ”the migraine market is so big and so unsatisfied that there is room for multiple therapies,” says CEO Deborah Dunsire.
Deborah Dunsire, CEO of Lundbeck | Photo: Gregers Tycho/ERH
by christian bundgaard, translated by daniel pedersen

Lundbeck’s sales performance within its strategic brands was strong in the year’s first quarter, during which three out four of the firm’s key drugs beat analysts’ expectations.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: Jens Dresling

    Lundbeck maintains guidance after exceeding expectations in Q1

    For subscribers

  • Photo: Dado Ruvic/REUTERS / X02714

    Pfizer to acquire migraine firm for over USD 11bn

    For subscribers

  • Photo: Michael M. Santiago/AFP / GETTY IMAGES NORTH AMERICA

    Lundbeck to delist in US

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Nu mangler kun en endelig vedtagelse i EU-Parlamentet, før lovforslag om at udskyde deadlines for nye krav til medicinsk udstyr. er en realitet. | Foto: Thomas Borberg/Ritzau Scanpix
Medtech

Another hurdle overcome in delaying MDR deadline

EU member countries have voted unanimously to adopt an EU Commission proposal to stagger the implementation of the new Medical Device Regulation. Now, only the EU Parliament’s vote remains. 
  • Asensus Surgical wins CE Mark for intelligent surgical unit under MDR rules
  • EU Commission to give more time for MDR transition

For subscribers

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk hopes to retain employees with share gift

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

Luja can potentially solve a long-lived UTI problem for people who need help with bladder control issues by using new micro-hole technology
Medtech

Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps

For subscribers

Foto: Coloplast/pr
Medtech

Coloplast launches male catheter featuring new technology

For subscribers

Foto: Coloplast / Pr
Medtech

Coloplast's bottom line disappoints in otherwise strong report

For subscribers

Further reading

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk hopes to retain employees with share gift

All Novo Nordisk employees have been offered 37 restricted stock units, which can be turned into real B shares in Aug. 2026.

For subscribers

Jessica Hill/AP/Ritzau Scanpix
Pharma & biotech

Ascendis Pharma CEO tight-lipped on potential assault on Novo Nordisk's mother lode

Jan Møller MIkkelsen, CEO of Ascendis Pharma, dodged a question at a conference about whether he is currently drawing up battle plans targeting the obesity and diabetes market. 

For subscribers

Foto: Mike Blake/Reuters/Ritzau Scanpix
Pharma & biotech

Eli Lilly to support production of diabetes drugs with USD 450m investment

The US-based drugmaker has now committed around USD 4bn to new manufacturing facilities in North Carolina.

For subscribers

Latest news

  • Top news from MedWatch this week – 3 Feb
  • Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps – 3 Feb
  • China accepts regulatory filing for ALK allergy tablet – 3 Feb
  • Another hurdle overcome in delaying MDR deadline – 3 Feb
  • Dupixent becomes ninefold blockbuster – 3 Feb
  • ALK forecasts lower growth in 2023 than strong 2022 result – 3 Feb
  • Unilabs and Siemens Healthineers enter million-euro strategic partnership – 3 Feb
  • Coloplast launches male catheter featuring new technology – 3 Feb
  • Novo Nordisk hopes to retain employees with share gift – 3 Feb
  • Coloplast's bottom line disappoints in otherwise strong report – 3 Feb
See all

Jobs

  • Supply Chain Manager

  • Clinical Operational Associate

  • Regulatory Affairs Professional

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Senior Clinical Project Manager

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Lead Data Architect

  • Application Manager

  • Medical Advisor (Metabolism)

  • Commercial Director

  • Experienced Patent Counsel

  • Sr. Director, Drug Safety Physician

  • Application Manager

See all jobs

Jobs

  • Supply Chain Manager

  • Clinical Operational Associate

  • Regulatory Affairs Professional

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Senior Clinical Project Manager

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Lead Data Architect

  • Application Manager

  • Medical Advisor (Metabolism)

  • Commercial Director

  • Experienced Patent Counsel

  • Sr. Director, Drug Safety Physician

  • Application Manager

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge